Cosentyx (secukinumab) is a human monoclonal antibody that selectively binds to and inhibits interleukin-17A (IL-17A). IL-17A is a naturally occurring cytokine that is involved in inflammatory and immune responses. Cosentyx was developed by Novartis Pharmaceuticals and was approved by the U.S. Food and Drug Administration (FDA) in 2015 for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy.

Mechanism of Action

IL-17A is a key cytokine involved in the pathogenesis of psoriasis. It stimulates the production of other pro-inflammatory cytokines and chemokines which promote the development of psoriatic plaques by recruiting and activating T cells and neutrophils. Cosentyx drug works by selectively blocking the interaction of IL-17A with its receptor. This inhibits the downstream inflammatory cascade driven by IL-17A, providing an effective treatment option for moderate to severe plaque psoriasis. By targeting a single specific cytokine rather than blocking multiple pathways, Cosentyx drug offers a more selective mechanism of action than other biologics. Uses Beyond Plaque Psoriasis

Uses Beyond Plaque Psoriasis

Given its mechanism of action targeting IL-17A, Cosentyx is also being investigated for other immune-mediated diseases where the IL-23/IL-17 axis is implicated, such as psoriatic arthritis, ankylosing spondylitis and non-radiographic axial spondyloarthritis. In Phase III trials, Cosentyx drug met the primary endpoint of ACR20 response at week 12 in patients with active psoriatic arthritis, with responses maintained through week 24. It is now FDA-approved for this indication. Cosentyx also demonstrated efficacy in reducing signs and symptoms in patients with active ankylosing spondylitis compared to placebo in Phase III trials. Based on these results, Cosentyx offers an important new treatment option for patients with plaque psoriasis as well as related inflammatory conditions.

Cosentyx is a novel, targeted biologic therapy that selectively binds to and inhibits IL-17A, a key cytokine driving the inflammation in psoriasis and other immune-mediated diseases. It demonstrated rapid, substantial and long-lasting clearance of psoriatic plaques in Phase III clinical trials. To date, Cosentyx has maintained a favorable safety profile. With once-monthly subcutaneous administration and approval for use in psoriatic arthritis and ankylosing spondylitis, Cosentyx drug represents an important advancement in the treatment of moderate to severe plaque psoriasis and related diseases. Further studies are ongoing to evaluate its efficacy in other IL-17 mediated conditions.

 Gets More Insights on: Cosentyx Drug